Palivizumab Biosimilar, N297A Mutant | Catalog C021P.NA

Palivizumab Biosimilar, N297A Mutant. Palivizumab biosimilar CHO stable cell line is available for licensing to manufacture the palivizumab biosimilar protein. The research grade palivizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available.

Product Specifications

Catalog No.	C021P.NA
Product Name	Palivizumab Biosimilar, N297A Mutant
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Anti-RSV Humanized Monoclonal Antibody
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Isotype	Human IgG1 N297A Mutant
Source/Host	Produced in the palivizumab biosimilar CHO stable cell line.
Specificity	Specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).

Properties & Storage

Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Formulation	0.2 µM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	Shipped with ice pack. Store immediately at recommended temperature.
Storage	12 months from receipt at -20 to -70°C; 1 month at 2 to 8°C. Avoid freeze-thaw cycles.

Background & Description

Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.